Tagreed Alkaltham: Apheresis – Precision in Blood Component Collection
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
”Apheresis: Precision in Blood Component Collection
Not all blood donations are the same.
Some are designed… with precision.
Apheresis is a specialized donation process that allows us to collect specific blood components while safely returning the rest to the donor.
Because in transfusion medicine, efficiency is not a luxury… it’s a necessity.
Platelet Apheresis (Single Donor Platelets):
Platelets are critical for patients with:
- Cancer
- Bone marrow failure
- Massive bleeding
With apheresis:
- We collect a high dose platelet unit from a single donor
- Reducing donor exposure for the patient
- Enhancing transfusion safety and compatibility
One donor. One therapeutic dose. One controlled outcome.
Plasma Apheresis:
Plasma carries:
- Clotting factors
- Proteins essential for survival
Used in:
- Trauma and massive transfusion
- Liver disease
- Plasma exchange therapies
With apheresis:
- We collect larger plasma volumes efficiently
- While maintaining donor safety
Supporting critical care… with targeted collection.
Red Cell Apheresis (Double RBC Collection):
Designed for:
- Patients with chronic transfusion needs
- Situations requiring specific blood types
With this method:
- We collect two units of red cells in one session
- From a single, eligible donor
Maximizing impact… without increasing donor burden.
Why Apheresis Matters?
Because it allows us to:
- Improve component quality
- Reduce patient exposure to multiple donors
- Optimize inventory during shortages
- Deliver targeted therapy, not just transfusion
Apheresis is not just a technique.
It is a reflection of how far transfusion medicine has evolved
- From collection…
- to precision driven care.
In modern blood banking, we don’t just collect blood… we design it to meet the patient’s exact need.”
Other posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support